PathMaker Neurosystems is pioneering a novel approach to treating amyotrophic lateral sclerosis (ALS) and other serious neurological disorders through non-invasive neuromodulation technologies. The company focuses on the development of devices that utilize multi-site direct current stimulation (Multi-Site DCS) to suppress neuronal hyperexcitability and promote the degradation of proteins that aggregate in motor neurons. This innovative technology aims to restore damaged neural pathways by normalizing overactivity and reducing protein buildup, thereby offering a new treatment paradigm for patients suffering from ALS and similar conditions.

The MyoRegulator® device is central to PathMaker's clinical efforts, with ongoing and completed trials evaluating its efficacy in various contexts, including ALS and post-stroke spasticity. The CALM study, funded by the U.S. Department of Defense, aims to assess the MyoRegulator's impact on motor neuron excitability in ALS patients, while other trials focus on its effectiveness in reducing spasticity in upper and lower limbs following strokes. These clinical studies are crucial for establishing the safety and feasibility of the MyoRegulator® device, with results expected to contribute significantly to the understanding and treatment of motor neuron disorders.

United States

PathMaker Neurosystems is a near-commercial stage neuromodulation company founded to commercialize recent advances in the development of non-invasive devices for the treatment of patients with serious neurological conditions. The company's technology is based on the premise that electrical fields can be used to stimulate the nervous system in a non-invasive manner, offering the potential to treat a wide range of neurological disorders.

PathMaker Neurosystems

Company Details